NASDAQ · NVDA
NVIDIA Corporation
$213.66-$1.72 (-0.8%)
NVIDIA Corporation’s quoted price sits in the upper half of its reported 52-week range, 12.21% below the high.
Loading market information…
NASDAQ · SDGR · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Schrödinger, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.22% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Schrödinger, Inc.’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of -$0.67. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Schrödinger, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 01:02 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 7, 2025 | -$0.82-15.49% vs estimate | $59.55M+9.04% vs estimate |
|---|
| Q4 2024 | Feb 26, 2025 | -$0.55-57.14% vs estimate | $88.32M+6.16% vs estimate |
|---|
| Q3 2024 | Nov 12, 2024 | -$0.52+13.33% vs estimate | $35.29M-57.58% vs estimate |
|---|
THE ANALYST VIEW
12 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $19.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$213.66-$1.72 (-0.8%)
NVIDIA Corporation’s quoted price sits in the upper half of its reported 52-week range, 12.21% below the high.
$310.34-$7.48 (-2.35%)
Veeva Systems Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.8% below the high.
$19.47-$0.22 (-1.12%)
Relay Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 8.46% below the high.
$13.08-$0.56 (-4.11%)
AbCellera Biologics Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.92% below the high.
$15.77+$0.39 (+2.54%)
Generate Biomedicines, Inc.’s quoted price sits in the lower half of its reported 52-week range, 30.44% below the high.
$11.20-$0.28 (-2.44%)
Certara, Inc.’s quoted price sits in the upper half of its reported 52-week range, 5.72% below the high.
$18.50$0.00 (0.0%)
Simulations Plus, Inc.’s quoted price sits in the upper half of its reported 52-week range, 11.95% below the high.
$1.20+$0.02 (+1.69%)
MindWalk Holdings Corp.’s quoted price sits in the lower half of its reported 52-week range, 59.87% below the high.
